Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Amgen (NQ:AMGN)

297.75 +0.90 (+0.30%)
Streaming Delayed Price Updated: 10:08 AM EDT, Jul 3, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Amgen

< Previous 1 2
...
7 8 9 10 11 12 13 14 15
...
54 55 Next >
Despite Medicare Negotiations, Americans May Still Have To Pay More For Prescription Drugs
Despite Medicare's first-ever negotiated drug prices under the Inflation Reduction Act, U.S. costs remain significantly higher than those in other wealthy nations, with some prices still more than... 
Via Benzinga
Topics Economy
(AMGN) - Analyzing Amgen's Short Interest
Via Benzinga
Patchy But Still Bullish
Two weeks ago we turned to a more bullish stance, which has proved to be correct, though we still await the explosive movement out of these consolidations. 
Via Talk Markets
Amgen Unusual Options Activity For August 29
Via Benzinga
Smart Money Is Betting Big In AMGN Options
Via Benzinga
Amgen Options Trading: A Deep Dive into Market Sentiment
Via Benzinga
The 9 Pharma Stocks To Watch — Including Viking, Roche And Amgen — Amid The Fast-Growing Obesity Drug Race
The race to develop the next big obesity treatment is on with leaders Lilly and Novo trying to keep their top slots. 
Via Investor's Business Daily
Intuit, Amgen And Sprott Uranium Miners ETF: CNBC's 'Final Trades'
Jason Snipe of Odyssey Capital Advisors likes Intuit Inc., after the company beat on the top and bottom lines, but missed on guidance. 
Via Benzinga
Eli Lilly Halves Zepbound Price In New Version Of Weight-Loss Drug
The single-dose vials will also increase supply, the drug giant says. 
Via Investor's Business Daily
Eli Lilly’s Path to the Next Trillion Market Capitalization
Eli Lilly and Co. (NYSE: LLY) is a pharmaceutical giant that's made headlines for its GLP-1/GIP weight loss drug Tirzepatide, aka Mounjaro, for Type 2 diabetes. 
Via MarketBeat
3 Unstoppable Dividend Stocks to Buy Right Now
These stocks are the A-team for income investors. 
Via The Motley Fool
US Stocks May Take a Breather After S&P 500's Impressive 8-Session Winning Streak: Strategist Says Market Will Hit Fresh Highs In Next 4 Weeks, But Warns Investors Of Potential Risks
The gravity-defying climb faces risk, as the index futures trade narrowly mixed in early trading on Tuesday. That said, the recent gains could keep traders wary of a potential pullback. 
Via Benzinga
Topics Stocks
ProInvestor Insights - August 2024
Our August newletter features insights from high-level Wall Street researchers, traders, analysts, and economists that you won’t find anywhere else. And AAII’s first-to-be-seen interview with legendary... 
Via Talk Markets
2 Dow Jones Dividend Stocks With Above-Average Yields to Buy Now and Hold for at Least a Decade
Investors seeking reliable dividend growth want to start with these two members of the Dow Jones Industrial Average. 
Via The Motley Fool
Topics Stocks
This Healthcare Giant Had 12 Products That Generated Double-Digit Growth Last Quarter and There's Still Many More in the Pipeline
Amgen has many growth opportunities ahead, and it also pays a fairly high dividend. 
Via The Motley Fool
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Medicare Slashes Merck, Novo, AstraZeneca Drug Prices Up To 79% In IRA Negotiations
The unveiled prices follow months of back-and-forth negotiation between the government and the companies. 
Via Investor's Business Daily
MarketBeat Week in Review – 8/5 - 8/9
Stocks were looking for direction to end the week, but next week may bring more volatility with the latest reading on inflation and the start of retail earnings 
Via MarketBeat
Topics Economy
Stock Market Rally Begins After Global Rout; Palantir, Eli Lilly, Fortinet Jump: Weekly Review
After Monday's panicked global sell-off, markets have calmed down. 
Via Investor's Business Daily
The Defensive Sectors And VIX Have NOT Given The All-Clear Signal
The market has been a rollercoaster lately, with the resilience of defensive sectors and the modest bounce in the technology sector painting an intriguing picture. 
Via Talk Markets
Topics Stocks
Here's Why Eli Lilly Stock Dropped 12% Last Month
News from a competitor gave investors an unwelcome dose of reality. 
Via The Motley Fool
Amgen's Mixed Q2 Results Highlight Obesity Drug Potential, Analysts Focus Shifts To Upcoming Clinical Readouts
Amgen posted mixed Q2 results. Analysts highlight upcoming clinical readouts in obesity and inflammatory disease as crucial. Despite some underperformance, growth prospects remain strong, with... 
Via Benzinga
Why Amgen Stock Is Down Today Despite Solid Q2 Results
Shares may have been likely to fall no matter what the company reported. 
Via The Motley Fool
Wall Street Poised For Second Day Of Gains While Bank Of Japan Makes Reassurances; Dollar Strengthens Against Yen, Crude Prices Surge: What's Driving Markets Wednesday?
The U.S. 
Via Benzinga
Amgen Faces Near-Term Challenges But Long-Term Growth Prospects Remain Strong: Analyst
Amgen reported a 20% year-over-year increase in second-quarter sales, reaching $8.39 billion, surpassing the $8.33 billion consensus. Guidance for 2024 includes adjusted EPS of $19.10-$20.10 and... 
Via Benzinga
Amgen's MariTide Weight Loss Potential: Stock Outlook
Amgen's shares fell 2.4% after-hours trading due to a mixed earnings release. MariTide, the company's weight loss drug, is in Phase II FDA trials. 
Via MarketBeat
Topics Intellectual Property
US Stocks Set To Extend Gains Despite Mixed Earnings, VIX Dips Back Toward Pre-Sell-Off Levels: Analyst Says Pullback Is A 'Growth Scare' And Not 'Calamity'
Wall Street could go from strength to strength as the index futures point to another session in the green as investors seek to put the worst behind. Volatility continued to drop, as evidenced by... 
Via Benzinga
Topics Stocks
AMGN Stock Earnings: Amgen Misses EPS, Beats Revenue for Q2 2024
AMGN stock results show that Amgen missed analyst estimates for earnings per share but beat on revenue for the second quarter of 2024. 
Via InvestorPlace
Amgen Undercuts Its Buy Point On Mixed Second-Quarter Report
Amgen stock fell late Tuesday after the biotech reported lighter-than-expected second-quarter profits, though sales beat. 
Via Investor's Business Daily
Wall Street Rebounds After Selloff, VIX Falls, Dollar Surges Against Yen: What's Driving Markets Tuesday?
U.S. stock markets saw a strong recovery on Tuesday, with both the S&P 500 and the Nasdaq 100 climbing over 2%, nearly offsetting Monday’s losses. Investors took advantage of recent volatility to buy... 
Via Benzinga
Topics Economy Stocks
< Previous 1 2
...
7 8 9 10 11 12 13 14 15
...
54 55 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.